Annual report
2934.TEDINET S100SX2D
Period2022-06-01 → 2023-05-31
Filed2024-02-21
StandardJapan GAAP
ConsolidatedYes
Data checks23 of 23 passed
Amends S100RRVE. Amended by S100SXUN (2024-02-21).
Key figures · 116
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥16.8bn | 2022-06-01 → 2023-05-31 | Cons. | Net sales |
| Revenue | ¥11.9bn | 2021-06-01 → 2022-05-31 | Cons. | Net sales |
| Operating income | −¥1.8bn | 2022-06-01 → 2023-05-31 | Cons. | Operating income |
| Operating income | ¥731m | 2021-06-01 → 2022-05-31 | Cons. | Operating income |
| Ordinary income | −¥1.8bn | 2022-06-01 → 2023-05-31 | Cons. | Ordinary income |
| Ordinary income | ¥712m | 2021-06-01 → 2022-05-31 | Cons. | Ordinary income |
| Profit before tax | −¥1.8bn | 2022-06-01 → 2023-05-31 | Cons. | Income before income taxes |
| Profit before tax | ¥700m | 2021-06-01 → 2022-05-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥1.9bn | 2022-06-01 → 2023-05-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥401m | 2021-06-01 → 2022-05-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥1.9bn | 2022-06-01 → 2023-05-31 | Cons. | Profit loss |
| Net income | ¥400m | 2021-06-01 → 2022-05-31 | Cons. | Profit loss |
| Total assets | ¥7.2bn | at 2023-05-31 | Cons. | Assets |
| Total assets | ¥6.1bn | at 2022-05-31 | Cons. | Assets |
| Total liabilities | ¥4.5bn | at 2023-05-31 | Cons. | Liabilities |
| Total liabilities | ¥1.9bn | at 2022-05-31 | Cons. | Liabilities |
| Net assets / equity | ¥2.7bn | at 2023-05-31 | Cons. | Net assets |
| Net assets / equity | ¥4.2bn | at 2022-05-31 | Cons. | Net assets |
| Net assets / equity | ¥1.3bn | at 2021-05-31d | Cons. | Net assets |
| Cash and deposits | ¥1.6bn | at 2023-05-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥3.0bn | at 2022-05-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.6bn | at 2023-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.0bn | at 2022-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.6bn | at 2021-05-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥1.8bn | 2022-06-01 → 2023-05-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥367m | 2021-06-01 → 2022-05-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥1.1bn | 2022-06-01 → 2023-05-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥860m | 2021-06-01 → 2022-05-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥1.5bn | 2022-06-01 → 2023-05-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥2.6bn | 2021-06-01 → 2022-05-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-410.6 | 2022-06-01 → 2023-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥90.64 | 2021-06-01 → 2022-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥86.68 | 2021-06-01 → 2022-05-31 | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥525.78 | at 2023-05-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥907.43 | at 2022-05-31 | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 34.1% | at 2023-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 67.8% | at 2022-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 9.7% | 2021-06-01 → 2022-05-31 | Cons. | Rate of return on equity (5-year summary) |
| Employees | 255 | at 2023-05-31 | Cons. | Number of employees |
| Employees | 278 | at 2022-05-31 | Cons. | Number of employees |
| Revenue | ¥9.4bn | 2022-06-01 → 2023-05-31 | Standalone | Net sales |
| Revenue | ¥9.3bn | 2021-06-01 → 2022-05-31 | Standalone | Net sales |
| Revenue | ¥8.5bn | 2020-06-01 → 2021-05-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥7.1bn | 2019-06-01 → 2020-05-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥6.1bn | 2018-06-01 → 2019-05-31d | Standalone | Net sales (5-year summary) |
| Operating income | −¥1.7bn | 2022-06-01 → 2023-05-31 | Standalone | Operating income |
| Operating income | ¥751m | 2021-06-01 → 2022-05-31 | Standalone | Operating income |
| Ordinary income | −¥1.7bn | 2022-06-01 → 2023-05-31 | Standalone | Ordinary income |
| Ordinary income | ¥724m | 2021-06-01 → 2022-05-31 | Standalone | Ordinary income |
| Ordinary income | ¥679m | 2020-06-01 → 2021-05-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥174m | 2019-06-01 → 2020-05-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥367m | 2018-06-01 → 2019-05-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | −¥1.7bn | 2022-06-01 → 2023-05-31 | Standalone | Income before income taxes |
| Profit before tax | ¥723m | 2021-06-01 → 2022-05-31 | Standalone | Income before income taxes |
| Net income | −¥1.7bn | 2022-06-01 → 2023-05-31 | Standalone | Profit loss |
| Net income | ¥450m | 2021-06-01 → 2022-05-31 | Standalone | Profit loss |
| Net income | ¥425m | 2020-06-01 → 2021-05-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥96m | 2019-06-01 → 2020-05-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥6m | 2018-06-01 → 2019-05-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥5.8bn | at 2023-05-31 | Standalone | Assets |
| Total assets | ¥5.3bn | at 2022-05-31 | Standalone | Assets |
| Total assets | ¥2.6bn | at 2021-05-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥2.0bn | at 2020-05-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.9bn | at 2019-05-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥3.1bn | at 2023-05-31 | Standalone | Liabilities |
| Total liabilities | ¥1.1bn | at 2022-05-31 | Standalone | Liabilities |
| Net assets / equity | ¥2.8bn | at 2023-05-31 | Standalone | Net assets |
| Net assets / equity | ¥4.2bn | at 2022-05-31 | Standalone | Net assets |
| Net assets / equity | ¥1.3bn | at 2021-05-31d | Standalone | Net assets |
| Net assets / equity | ¥843m | at 2020-05-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥746m | at 2019-05-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥814m | at 2023-05-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥2.4bn | at 2022-05-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥1.6bn | at 2021-05-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥902m | at 2020-05-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥948m | at 2019-05-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥831m | 2020-06-01 → 2021-05-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥218m | 2019-06-01 → 2020-05-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥14m | 2018-06-01 → 2019-05-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥8m | 2020-06-01 → 2021-05-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥165m | 2019-06-01 → 2020-05-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥63m | 2018-06-01 → 2019-05-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥94m | 2020-06-01 → 2021-05-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥99m | 2019-06-01 → 2020-05-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥130m | 2018-06-01 → 2019-05-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-357.08 | 2022-06-01 → 2023-05-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥101.91 | 2021-06-01 → 2022-05-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥110.75 | 2020-06-01 → 2021-05-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥25.12 | 2019-06-01 → 2020-05-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥1.6 | 2018-06-01 → 2019-05-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥97.45 | 2021-06-01 → 2022-05-31 | Standalone | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥589.16 | at 2023-05-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥918.35 | at 2022-05-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥329.99 | at 2021-05-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥219.25 | at 2020-05-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥194.13 | at 2019-05-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 47.4% | at 2023-05-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 79.0% | at 2022-05-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 48.8% | at 2021-05-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.5% | at 2020-05-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 39.0% | at 2019-05-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | -47.5% | 2022-06-01 → 2023-05-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 16.5% | 2021-06-01 → 2022-05-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 40.3% | 2020-06-01 → 2021-05-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 12.2% | 2019-06-01 → 2020-05-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 0.8% | 2018-06-01 → 2019-05-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 4,892,098 | at 2023-05-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,757,616 | at 2022-05-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,918,500 | at 2021-05-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,918,500 | at 2020-05-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,918,500 | at 2019-05-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 49 | at 2023-05-31 | Standalone | Number of employees |
| Employees | 54 | at 2022-05-31 | Standalone | Number of employees |
| Employees | 46 | at 2021-05-31d | Standalone | Number of employees |
| Employees | 47 | at 2020-05-31d | Standalone | Number of employees |
| Employees | 42 | at 2019-05-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 71
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2022-06-01 → 2023-05-31 | ¥2m |
| Reconciling Itemsreconciling | depreciation | 2022-06-01 → 2023-05-31 | ¥765,000 |
| Reconciling Itemsreconciling | revenue | 2022-06-01 → 2023-05-31 | −¥186m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-06-01 → 2023-05-31 | −¥186m |
| Reconciling Itemsreconciling | segment assets | at 2023-05-31 | ¥1.3bn |
| Reconciling Itemsreconciling | segment profit | 2022-06-01 → 2023-05-31 | −¥729m |
| Healthcare Marketing Businessreportable segment | capex | 2022-06-01 → 2023-05-31 | ¥4m |
| Healthcare Marketing Businessreportable segment | depreciation | 2022-06-01 → 2023-05-31 | ¥5m |
| Healthcare Marketing Businessreportable segment | employees | at 2023-05-31 | 48 pure |
| Healthcare Marketing Businessreportable segment | revenue | 2022-06-01 → 2023-05-31 | ¥5.2bn |
| Healthcare Marketing Businessreportable segment | revenue external | 2022-06-01 → 2023-05-31 | ¥5.1bn |
| Healthcare Marketing Businessreportable segment | revenue intersegment | 2022-06-01 → 2023-05-31 | ¥185m |
| Healthcare Marketing Businessreportable segment | segment assets | at 2023-05-31 | ¥1.1bn |
| Healthcare Marketing Businessreportable segment | segment profit | 2022-06-01 → 2023-05-31 | ¥39m |
| Healthcare Sales Businessreportable segment | capex | 2022-06-01 → 2023-05-31 | ¥1.1bn |
| Healthcare Sales Businessreportable segment | depreciation | 2022-06-01 → 2023-05-31 | ¥4m |
| Healthcare Sales Businessreportable segment | employees | at 2023-05-31 | 48 pure |
| Healthcare Sales Businessreportable segment | revenue | 2022-06-01 → 2023-05-31 | ¥4.1bn |
| Healthcare Sales Businessreportable segment | revenue external | 2022-06-01 → 2023-05-31 | ¥4.1bn |
| Healthcare Sales Businessreportable segment | segment assets | at 2023-05-31 | ¥2.4bn |
| Healthcare Sales Businessreportable segment | segment profit | 2022-06-01 → 2023-05-31 | −¥28m |
| Medical Care Sales Businessreportable segment | capex | 2022-06-01 → 2023-05-31 | ¥288m |
| Medical Care Sales Businessreportable segment | depreciation | 2022-06-01 → 2023-05-31 | ¥14m |
| Medical Care Sales Businessreportable segment | employees | at 2023-05-31 | 144 pure |
| Medical Care Sales Businessreportable segment | revenue | 2022-06-01 → 2023-05-31 | ¥7.7bn |
| Medical Care Sales Businessreportable segment | revenue external | 2022-06-01 → 2023-05-31 | ¥7.7bn |
| Medical Care Sales Businessreportable segment | revenue intersegment | 2022-06-01 → 2023-05-31 | ¥564,000 |
| Medical Care Sales Businessreportable segment | segment assets | at 2023-05-31 | ¥2.4bn |
| Medical Care Sales Businessreportable segment | segment profit | 2022-06-01 → 2023-05-31 | −¥1.1bn |
| —segment total | employees | at 2023-05-31 | 255 pure |
| Total Of Reportable Segments And Otherssegment total | capex | 2022-06-01 → 2023-05-31 | ¥1.4bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2022-06-01 → 2023-05-31 | ¥23m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-06-01 → 2023-05-31 | ¥17.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-06-01 → 2023-05-31 | ¥16.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-06-01 → 2023-05-31 | ¥186m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2023-05-31 | ¥5.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-06-01 → 2023-05-31 | −¥1.1bn |
| Reconciling Itemsreconciling | capex | 2021-06-01 → 2022-05-31 | ¥5m |
| Reconciling Itemsreconciling | depreciation | 2021-06-01 → 2022-05-31 | ¥5m |
| Reconciling Itemsreconciling | revenue | 2021-06-01 → 2022-05-31 | −¥54m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-06-01 → 2022-05-31 | −¥54m |
| Reconciling Itemsreconciling | segment assets | at 2022-05-31 | ¥2.7bn |
| Reconciling Itemsreconciling | segment profit | 2021-06-01 → 2022-05-31 | −¥425m |
| Healthcare Marketing Businessreportable segment | capex | 2021-06-01 → 2022-05-31 | ¥362m |
| Healthcare Marketing Businessreportable segment | depreciation | 2021-06-01 → 2022-05-31 | ¥2m |
| Healthcare Marketing Businessreportable segment | revenue | 2021-06-01 → 2022-05-31 | ¥3.9bn |
| Healthcare Marketing Businessreportable segment | revenue external | 2021-06-01 → 2022-05-31 | ¥3.8bn |
| Healthcare Marketing Businessreportable segment | revenue intersegment | 2021-06-01 → 2022-05-31 | ¥54m |
| Healthcare Marketing Businessreportable segment | segment assets | at 2022-05-31 | ¥1.3bn |
| Healthcare Marketing Businessreportable segment | segment profit | 2021-06-01 → 2022-05-31 | ¥37m |
| Healthcare Sales Businessreportable segment | depreciation | 2021-06-01 → 2022-05-31 | ¥703,000 |
| Healthcare Sales Businessreportable segment | revenue | 2021-06-01 → 2022-05-31 | ¥3.0bn |
| Healthcare Sales Businessreportable segment | revenue external | 2021-06-01 → 2022-05-31 | ¥3.0bn |
| Healthcare Sales Businessreportable segment | segment assets | at 2022-05-31 | ¥251m |
| Healthcare Sales Businessreportable segment | segment profit | 2021-06-01 → 2022-05-31 | ¥779m |
| Medical Care Sales Businessreportable segment | capex | 2021-06-01 → 2022-05-31 | ¥588m |
| Medical Care Sales Businessreportable segment | depreciation | 2021-06-01 → 2022-05-31 | ¥3m |
| Medical Care Sales Businessreportable segment | revenue | 2021-06-01 → 2022-05-31 | ¥5.0bn |
| Medical Care Sales Businessreportable segment | revenue external | 2021-06-01 → 2022-05-31 | ¥5.0bn |
| Medical Care Sales Businessreportable segment | segment assets | at 2022-05-31 | ¥1.9bn |
| Medical Care Sales Businessreportable segment | segment profit | 2021-06-01 → 2022-05-31 | ¥339m |
| Total Of Reportable Segments And Otherssegment total | capex | 2021-06-01 → 2022-05-31 | ¥950m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2021-06-01 → 2022-05-31 | ¥5m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-06-01 → 2022-05-31 | ¥11.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-06-01 → 2022-05-31 | ¥11.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-06-01 → 2022-05-31 | ¥54m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2022-05-31 | ¥3.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-06-01 → 2022-05-31 | ¥1.2bn |
| Healthcare Marketing Businessreportable segment | employees | at 2023-05-31 | 10 pure |
| Healthcare Sales Businessreportable segment | employees | at 2023-05-31 | 19 pure |
| Medical Care Sales Businessreportable segment | employees | at 2023-05-31 | 8 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,468
| Item | Context | Value | Unit |
|---|---|---|---|
| Depreciation segment information | CurrentYearDuration | 23664000 | JPY |
| Amortization of goodwill sga | CurrentYearDuration_jpcrp030000-asr_E33800-000MedicalCareSalesBusinessReportableSegmentMember | 57311000 | JPY |
| Amortization of goodwill sga | CurrentYearDuration_jpcrp030000-asr_E33800-000HealthcareSalesBusinessReportableSegmentMember | 78730000 | JPY |
| Amortization of goodwill sga | CurrentYearDuration_jpcrp030000-asr_E33800-000HealthcareMarketingBusinessReportableSegmentMember | 38383000 | JPY |
| Amortization of goodwill sga | CurrentYearDuration_TotalOfReportableSegmentsAndOthersMember | 174425000 | JPY |
| Amortization of goodwill sga | CurrentYearDuration_ReconcilingItemsMember | － | JPY |
| Amortization of goodwill sga | CurrentYearDuration | 174425000 | JPY |
| Amortization of customer related assets | CurrentYearDuration_jpcrp030000-asr_E33800-000MedicalCareSalesBusinessReportableSegmentMember | 10584000 | JPY |
| Amortization of customer related assets | CurrentYearDuration_jpcrp030000-asr_E33800-000HealthcareSalesBusinessReportableSegmentMember | 85512000 | JPY |
| Amortization of customer related assets | CurrentYearDuration_jpcrp030000-asr_E33800-000HealthcareMarketingBusinessReportableSegmentMember | － | JPY |
| Amortization of customer related assets | CurrentYearDuration_TotalOfReportableSegmentsAndOthersMember | 96097000 | JPY |
| Amortization of customer related assets | CurrentYearDuration_ReconcilingItemsMember | － | JPY |
| Amortization of customer related assets | CurrentYearDuration | 96097000 | JPY |
| Unamortized balance of goodwill | CurrentYearDuration_jpcrp030000-asr_E33800-000MedicalCareSalesBusinessReportableSegmentMember | 613840000 | JPY |
| Unamortized balance of goodwill | CurrentYearDuration_jpcrp030000-asr_E33800-000HealthcareSalesBusinessReportableSegmentMember | 780144000 | JPY |
| Unamortized balance of goodwill | CurrentYearDuration_jpcrp030000-asr_E33800-000HealthcareMarketingBusinessReportableSegmentMember | 278162000 | JPY |
| Unamortized balance of goodwill | CurrentYearDuration_TotalOfReportableSegmentsAndOthersMember | 1672147000 | JPY |
| Unamortized balance of goodwill | CurrentYearDuration_ReconcilingItemsMember | － | JPY |
| Unamortized balance of goodwill | CurrentYearDuration | 1672147000 | JPY |
| Increase in property plant and equipment and intangible assets | CurrentYearDuration_jpcrp030000-asr_E33800-000MedicalCareSalesBusinessReportableSegmentMember | 288067000 | JPY |
| Increase in property plant and equipment and intangible assets | CurrentYearDuration_jpcrp030000-asr_E33800-000HealthcareSalesBusinessReportableSegmentMember | 1111421000 | JPY |
| Increase in property plant and equipment and intangible assets | CurrentYearDuration_jpcrp030000-asr_E33800-000HealthcareMarketingBusinessReportableSegmentMember | 4466000 | JPY |
| Increase in property plant and equipment and intangible assets | CurrentYearDuration_TotalOfReportableSegmentsAndOthersMember | 1403954000 | JPY |
| Increase in property plant and equipment and intangible assets | CurrentYearDuration_ReconcilingItemsMember | 1617000 | JPY |
| Increase in property plant and equipment and intangible assets | CurrentYearDuration | 1405572000 | JPY |
| Cash and deposits | Prior1YearInstant_NonConsolidatedMember | 2414638000 | JPY |
| Cash and deposits | CurrentYearInstant_NonConsolidatedMember | 814424000 | JPY |
| Accounts receivable trade | Prior1YearInstant_NonConsolidatedMember | 896059000 | JPY |
| Accounts receivable trade | CurrentYearInstant_NonConsolidatedMember | 1043341000 | JPY |
| Merchandise | Prior1YearInstant_NonConsolidatedMember | 316778000 | JPY |
| Merchandise | CurrentYearInstant_NonConsolidatedMember | 244061000 | JPY |
| Supplies | Prior1YearInstant_NonConsolidatedMember | 8002000 | JPY |
| Supplies | CurrentYearInstant_NonConsolidatedMember | 6868000 | JPY |
| Advance payments trade | Prior1YearInstant_NonConsolidatedMember | － | JPY |
| Advance payments trade | CurrentYearInstant_NonConsolidatedMember | 14743000 | JPY |
| Prepaid expenses | Prior1YearInstant_NonConsolidatedMember | 100712000 | JPY |
| Prepaid expenses | CurrentYearInstant_NonConsolidatedMember | 103547000 | JPY |
| Short term loans receivable to subsidiaries and affiliates | Prior1YearInstant_NonConsolidatedMember | 130000000 | JPY |
| Short term loans receivable to subsidiaries and affiliates | CurrentYearInstant_NonConsolidatedMember | 232000000 | JPY |
| Other ca | Prior1YearInstant_NonConsolidatedMember | 9325000 | JPY |
| Other ca | CurrentYearInstant_NonConsolidatedMember | 259710000 | JPY |
| Allowance for doubtful accounts ca | Prior1YearInstant_NonConsolidatedMember | -3788000 | JPY |
| Allowance for doubtful accounts ca | CurrentYearInstant_NonConsolidatedMember | -4961000 | JPY |
| Current assets | Prior1YearInstant_NonConsolidatedMember | 3871728000 | JPY |
| Current assets | CurrentYearInstant_NonConsolidatedMember | 2713735000 | JPY |
| Buildings and accompanying facilities | Prior1YearInstant_NonConsolidatedMember | 1797000 | JPY |
| Buildings and accompanying facilities | CurrentYearInstant_NonConsolidatedMember | 1252000 | JPY |
| Tools furniture and fixtures | Prior1YearInstant_NonConsolidatedMember | 7389000 | JPY |
| Tools furniture and fixtures | CurrentYearInstant_NonConsolidatedMember | 5242000 | JPY |
| Property plant and equipment | Prior1YearInstant_NonConsolidatedMember | 9187000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 23 of 23 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |